4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Glioma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 1563 ongoing clinical trials involving Glioma
Of the 1563 trials,484 trials are in Phase II
Furthermore, 370 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Glioma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Glioma, an oncology condition. The largest number of ongoing clinical trials for Glioma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Glioma-related drug trials.

National Cancer Institute US: The leading ongoing Glioma related clinical trial sponsor

National Cancer Institute US is the top sponsor for Glioma-related ongoing clinical trials.

University of Texas MD Anderson Cancer Center, University of California San Francisco, and Children's Oncology Group are among other notable clinical trial sponsors involved in Glioma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Glioma

Bevacizumab (Avastin), Everolimus (Afinitor, Votubia, RAD001), and Bevacizumab biosimilar (Mvasi), Bevacizumab biosimilar (Zirabev) are among the key marketed drugs involving Glioma.

Bevacizumab (Avastin) is a recombinant humanized monoclonal IgG1 antibody. It functions via Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor mechanism of action. It is formulated as injection for intravenous administration. Avastin is marketed for the treatment of Glioma and several other indications including Breast Cancer, Lung Cancer, Ovarian Cancer, Glioblastoma Multiforme (GBM), Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Colorectal Cancer, Cervical Cancer. Avastin was first approved in 2004 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by F. Hoffmann-La Roche Ltd and its subsidiaries.

Everolimus (Afinitor, Votubia, RAD001) is an ester of the macrocytic immunosuppressive agent and acts as an anti-neoplastic agent. It functions via Serine/Threonine Protein Kinase mTOR (FK506 Binding Protein 12 Rapamycin Complex Associated Protein 1 or FKBP12 Rapamycin Complex Associated Protein or Mammalian Target Of Rapamycin or Mechanistic Target Of Rapamycin or Rapamycin And FKBP12 Target 1 or Rapamycin Target Protein 1 or MTOR or EC 2.7.11.1) Inhibitor mechanism of action. It is formulated as tablets for oral administration. Everolimus is marketed for the treatment of Glioma and several other indications including Epilepsy, Ovarian Cancer, Osteosarcoma, Ewing Sarcoma, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Thyroid Cancer, Fallopian Tube Cancer, Ependymoma, Cutaneous T-Cell Lymphoma, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). Everolimus was first approved in 2009 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Novartis AG and its subsidiaries.